(Q34457474)

2 August 2017

1 reference

title

Gonadotropin-releasing-hormone-receptor antagonists (English)

1 reference

2 August 2017

J A Huirne

1

1 reference

PubMed ID

11734258

2 August 2017

C B Lambalk

series ordinal

2

1 reference

PubMed ID

11734258

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

358

1 reference

2 August 2017

9295

1 reference

2 August 2017

1793-1803

1 reference

Gonadotropin-releasing hormone and its analogs

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Local Regulation of Gonadotroph Function by Pituitary Gonadotropin-Releasing Hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Human luteinizing hormone-releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2----p21).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Second gene for gonadotropin-releasing hormone in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Sequence alignment of the G-protein coupled receptor superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Mapping of the gonadotropin-releasing hormone (GnRH) receptor gene to human chromosome 4q21.2 by fluorescence in situ hybridization.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

A novel mammalian receptor for the evolutionarily conserved type II GnRH

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Subregional mapping of the human gonadotropin-releasing hormone receptor (GnRH-R) gene to 4q between the markers D4S392 and D4S409.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Effects of LHRH-analogues on mitogenic signal transduction in cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone in human granulosa-luteal cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

A chicken gonadotropin-releasing hormone receptor that confers agonist activity to mammalian antagonists. Identification of D-Lys(6) in the ligand and extracellular loop two of the receptor as determinants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

1 reference

7 January 2021

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Gonadotropin-releasing hormone antagonists with N.omega.-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Development of GnRH antagonists for prostate cancer: new approaches to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Antarelix (EP 24332) a novel water soluble LHRH antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Decreased release of gonadotropin-releasing hormone during the preovulatory midcycle luteinizing hormone surge in normal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Effects of gonadotrophin releasing hormone antagonist and agonist on the pulsatile release of gonadotrophins and alpha-subunit in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Potent pituitary-gonadal axis suppression and extremely low anaphylactoid activity of a new gonadotropin releasing hormone (GnRH) receptor antagonist "azaline B".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Controlled ovarian hyperstimulation in assisted reproduction: effect on the immune system.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Direct ovarian effects and safety aspects of GnRH agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Effect of the gonadotropin-releasing hormone antagonist ganirelix on cyclic adenosine monophosphate accumulation of human granulosa-lutein cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

The role of gonadotropin-releasing hormone in murine preimplantation embryonic development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Gonadotropin-Releasing Hormone Increases Cleavage Rates of Bovine Oocytes Fertilized in Vitro1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Gonadotrophin-releasing hormone antagonists inhibit sperm binding to the human zona pellucida

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Time to revolutionize ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Reducing the Risk of Multiple Births by Transfer of Two Embryos after in Vitro Fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

GnRH antagonist in single-dose applications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Primary and salvage therapy with LH-RH analogues in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Hormonal treatment of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Gonadotropin-Releasing Hormone (GnRH)-Binding Sites in Human Breast Cancer Cell Lines and Inhibitory Effects of GnRH Antagonists*

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Luteinizing hormone-releasing hormone antagonists in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Pharmacologic treatment of hypersexuality and paraphilias in nursing home residents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906797-6

7 January 2021

10.1016/S0140-6736(01)06797-6

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11734258